Clinical trials: Advanced Parkinson's Disease
Parkinson Disease
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability
- Trial name
- NCT02248220
- Testing
- Pramipexole
- Volunteers
- 657 people
- Sponsor
- Boehringer Ingelheim
Advanced Stage Parkinson's Disease
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.
- Trial name
- NCT00903838
- Testing
- pardoprunox, pramipexole
- Where
- 9 sites in Germany, Italy and 1 more
- Volunteers
- 37 people
- Sponsor
- Abbott Products
Dyskinesias, Parkinson Disease
Effects of Talampanel on Patients With Advanced Parkinson's Disease
The purpose of this research study is to test the safety and effectiveness of the study drug, Talampanel, when used to treat patients with involuntary movements known as dyskinesias, as a result of treatment to Parkinson's…
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders
- Trial name
- NCT00036296
- Testing
- talampanel
- Volunteers
- 22 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor…
- Trial name
- ATLANTIS (NCT06055985)
- Testing
- UCB0022
- Where
- 61 sites in United States
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Parkinson's Disease
A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
This is a randomized, open-label, rater-blinded, multicenter, 3-treatment, 3 period, single-dose crossover study. Approximately 51 qualified immediate-release (IR) CD-LD-experienced advanced Parkinson's disease patients will be…
- Trial name
- NCT02271503
- Testing
- CD-LD IR, IPX203 180 mg, IPX203 270 mg
- Where
- 11 sites in United States
- Volunteers
- 26 people
- Sponsor
- Impax Laboratories, LLC
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec
Parkinson Disease, Movement Disorders
Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of bilateral stimulation of the subthalamic nucleus (STN) of the brain when using the ANS Totally Implantable Deep Brain Stimulation System as an adjunctive…
- Trial name
- NCT00552474
- Testing
- Libra Deep Brain Stimulation System
- Where
- 15 sites in United States
- Volunteers
- 136 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease (PD)
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.
- Trial name
- COSMOS (NCT03362879)
- Where
- 30 sites in Austria, Canada and 9 more
- Volunteers
- 412 people
- Sponsor
- AbbVie
Advanced Parkinson's Disease
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
- Trial name
- NCT02549092
- Testing
- Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 89 people
- Sponsor
- AbbVie
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
- Trial name
- NCT07422675
- Testing
- SER-252 (PEOZ-apomorphine), enFuse
- Where
- 6 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Serina Therapeutics
Advanced Idiopathic Parkinson's Disease
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with…
- Trial name
- REFRESH-PD (NCT01519882)
- Testing
- Rotigotine
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- UCB Pharma SA
Parkinson's Disease
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person.
- Trial name
- P25-758 PUCCIN (NCT07227896)
- Where
- 10 sites in United States, Israel and 2 more
- Volunteers
- 100 people
- Sponsor
- AbbVie
Advanced Parkinson Disease
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
- Trial name
- ELEGANCE (NCT05043103)
- Testing
- Lecigon® based on European Medicines Agency (EMA) SmPC
- Where
- 57 sites in Austria, Belgium and 12 more
- Volunteers
- 312 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Advanced Idiopathic Parkinson's Disease
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and…
- Trial name
- NCT01711866
- Testing
- Rotigotine
- Where
- 21 sites in United States, Malaysia and 3 more
- Volunteers
- 87 people
- Sponsor
- UCB BIOSCIENCES GmbH
Parkinson's Disease
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease…
- Trial name
- NCT00134251
- Testing
- SLV308
- Where
- 10 sites in Bulgaria, Malta and 1 more
- Sponsor
- Solvay Pharmaceuticals
Levodopa-induced Dyskinesia
Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia
The purpose of this study is to determine the safety, tolerability, pharmacokinetic and pharmacodynamic effects of single doses of Neu-120 in Parkinson's disease patients with levodopa-induced dyskinesia.
- Trial name
- NCT00607451
- Testing
- Neu-120
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
- Trial name
- NCT00203177
- Testing
- rasagiline mesylate, rasagiline mesylate 1.0 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 254 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
- Trial name
- NCT01130493
- Testing
- IPX066, CLE
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 110 people
- Sponsor
- Impax Laboratories, LLC
Parkinson''s Disease
Pilot Study of Safety and Efficacy of Spheramine
Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease
- Trial name
- NCT00761436
- Testing
- Spheramine (BAY86-5280)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bayer